Vicore Pharma Holding (VICO) Stock Overview
A clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VICO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vicore Pharma Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 7.35 |
| 52 Week High | SEK 19.70 |
| 52 Week Low | SEK 6.09 |
| Beta | 0.38 |
| 1 Month Change | -13.73% |
| 3 Month Change | 12.39% |
| 1 Year Change | -61.07% |
| 3 Year Change | -71.62% |
| 5 Year Change | -59.95% |
| Change since IPO | 3.52% |
Recent News & Updates
Recent updates
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Apr 24
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Sep 11Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans
Feb 10We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
Sep 21We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
May 25Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)
Jan 10Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?
Nov 13Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation
Jul 26Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?
Mar 03What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition
Jan 11
Shareholder Returns
| VICO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.7% | 0.4% | 1.0% |
| 1Y | -61.1% | -7.0% | -3.1% |
Return vs Industry: VICO underperformed the Swedish Biotechs industry which returned -7% over the past year.
Return vs Market: VICO underperformed the Swedish Market which returned -3.1% over the past year.
Price Volatility
| VICO volatility | |
|---|---|
| VICO Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: VICO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VICO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 33 | Ahmed Mousa | www.vicorepharma.com |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.
Vicore Pharma Holding AB (publ) Fundamentals Summary
| VICO fundamental statistics | |
|---|---|
| Market cap | SEK 1.72b |
| Earnings (TTM) | -SEK 311.88m |
| Revenue (TTM) | SEK 6.00m |
Is VICO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VICO income statement (TTM) | |
|---|---|
| Revenue | SEK 6.00m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.00m |
| Other Expenses | SEK 317.88m |
| Earnings | -SEK 311.88m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 22, 2025
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,202.40% |
| Debt/Equity Ratio | 0% |
How did VICO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/14 23:08 |
| End of Day Share Price | 2025/07/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vicore Pharma Holding AB (publ) is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gonzalo Artiach Castanon | Danske Bank |
| Patrik Ling | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |